BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for &lt;i&gt;BRAF&lt;/i&gt; V600E-mutant metastatic colorectal cancer. The gene discussed is BRAF; the disease is metastatic colorectal cancer.